Skip to main content
. 2011 May 6;301(1):H87–H97. doi: 10.1152/ajpheart.01206.2010

Fig. 2.

Fig. 2.

DOX treatment did not alter middle cerebral artery (MCA) reactivity to 5-hydroxytriptamine (5-HT; A) and bradykinin (BK; B) and did not alter MCA myogenic response to increases in intralumenal pressure (C). MCAs were maintained at 80 mmHg of intralumenal pressure, and drugs were added to the bath in a cumulative fashion. The vessel was allowed to equilibrate for 10 min at every dose to reach steady state. To assess myogenic tone (C), intralumenal pressure was increased from 3 to 180 mmHg in 20-mmHg increments, and the vessel was allowed to equilibrate for 5 min at each pressure before measurement was taken. Values are means ± SE. Data were analyzed by two-way repeated-measures ANOVA.